Vimarsana
Biggest News Aggregation in the World

Page 33 - Accessed March News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Accessed March. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Accessed March Today - Breaking & Trending Today

Food System Developments and the Future of Our Planet - Vimarsana News

Food System Developments and the Future of Our Planet

March 21 is National Agriculture Day, recognizing and celebrating the contribution of agriculture to our daily lives. Understanding how food is produced and how agriculture ensures the world’s population can access safe and abundant food is essential.

Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer - Vimarsana News

Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer

/PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced positive...

TREMFYA® (guselkumab) Real-World Data Analyses Show Greater Treatment Persistence Than IL-17s in Both Bio-naïve and Bio-experienced Patients Living With Moderate to Severe Plaque Psoriasis - Vimarsana News

TREMFYA® (guselkumab) Real-World Data Analyses Show Greater Treatment Persistence Than IL-17s in Both Bio-naïve and Bio-experienced Patients Living With Moderate to Severe Plaque Psoriasis

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data, showing that initiation of TREMFYA® (guselkumab) was...

NDA Submitted for Niraparib Plus Abiraterone Acetate + Prednisone for Prostate Cancer - Vimarsana News

NDA Submitted for Niraparib Plus Abiraterone Acetate + Prednisone for Prostate Cancer

The NDA for niraparib plus abiraterone acetate and prednisone has been submitted to the FDA for patients with BRCA-positive mCRPC.

Prostate Cancer Treatment Pluvicto Currently in Shortage - Vimarsana News

Prostate Cancer Treatment Pluvicto Currently in Shortage

Pluvicto (lutetium Lu 177 vipivotide tetraxetan injection) is currently in shortage due to challenges in meeting demand.